Bayer appoints Cardinal Health as U.S. based contract manufacturer for Xofigo®
Bayer and Cardinal Health announced the signing of a 15-year agreement for the contract manufacturing of Xofigo® (radium Ra 223 dichloride). Cardinal Health will build a state-of-the art, 64,000 square foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo. December 18, 2014